AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06751914 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional second-line therapy
Description: Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
Study NCT06751914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06755190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: AI-Based Diagnostic and Prognostic Model for Ocular Diseases
Description: This intervention involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. It integrates multi-modal data, including fundus photography, optical coherence tomography (OCT), and patient clinical records, to provide real-time, precise, and personalized diagnostic support. Unlike other models, this system utilizes a longitudinal patient dataset to predict disease progression and treatment outcomes.Key distinguishing features include: 1. Multi-Modal Data Integration: Combines imaging, clinical, and genetic data for comprehensive analysis. 2. Predictive Capability: Offers advanced prognostic predictions, enabling personalized treatment plans. 3. Deep Learning Framework: Employs state-of-the-art deep learning algorithms for improved diagnostic accuracy and efficiency. 4. Real-World Validation: Validated using a large cohort of diverse patient data, ensuring generalizability and robustness.
Study NCT06755099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: The patient will be placed in gynecological position. Subsequently, the patient will be anesthetized with propofol bolus, a total of 270 mg IV sterilization of valval area with antiseptic solution then digital examination to assess the spasm of intriotus and vaginal walls under lowest possible doses then increasing the doses to allow for intra vaginal injection of Botox under full sedation. Pacik technique will be adopted for Botox Injection in the vagina .~. One vial of frozen Botox 100 U will be diluted with 2 mL saline, without foaming or shaking the vial, giving a concentration of 2.5 U/0.05 mL . Using a small sized speculum and after bending the needle to 30° to facilitate injection into sub mucosal area,1 mL (50 U) of Botox will be injected into the right bulbocavernosus then into the left side .
Study NCT06755099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Patients will be placed in prone position. After proper disinfection, the ischial spine (IS) and insertion point of the sacrospinous ligament will be identified using fluoroscopy medial to IS. 5 ml Lidocaine 2 % will be used to apply local anesthesia to the skin at the expected entry point for the radiofrequency cannula. Then a 20 G, 10 cm long and 1 cm active tip radiofrequency cannula will be introduced gradually utilizing 2 Hz motor stimulation until pudendal nerve is identified visually by the occurrence of contraction of the external anal sphincter muscle.~Subsequently, pulsed radiofrequency lesioning at temperature limit of 42 C will be applied bilaterally to the pudendal nerves for 240 s (2 cycles of 120 s) after applying local anesthesia using 2 cm 2% lidocaine in its vicinity.
Study NCT06446154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.
Study NCT05645328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iowa Cancer Affiliate Network (ICAN)
Description: Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
Study NCT06189976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid atrial pacing
Description: Rapid atrial pacing after TAVI
Study NCT04791189 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire to survey the needs of adolescents with juvenile idiopathic arthritis and the views of their parents in the area of sexual health.
Study NCT05099185 — intervention group
Intervention type: BIOLOGICAL
Intervention: Water-soluble vitamins and trace elements measures
Description: We would like to measure water-soluble vitamins (B1, B6, B9, B12, C) and trace elements (zinc, selenium) in blood and dialysate for the patients treated by online post-dilution hemodiafiltration patients. There measures on blood are done systematically during the half-yearly report of our patients in our hemodialysis center. Only results are collect for the study.
Study NCT06104254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: we will give an education to experimental group about pain and pain management.
Study NCT05458999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality headset during percutaneous coronary intervention
Description: Virtual reality glasses during percutaneous coronary intervention
Study NCT06379763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy exercise
Description: conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
Study NCT06379763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy exercise
Description: conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
Study NCT05811455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
Study NCT05811455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: progressive muscle relaxation exercises.
Study NCT05728619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTMC0435
Description: Oral administration.
Study NCT05162703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Description: Exercise challenge test using AsthmaTuner mobile phone app and spirometer.
Study NCT05728619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral administration.
Study NCT05650684 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
Study NCT04881864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Enhance Fitness
Description: Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
Study NCT06237738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball Use
Description: The intervention in this study involves the use of stress balls provided to participants in the intervention group. These are specially designed medium-firm silicone balls intended for squeezing with the hand opposite the one receiving cannulation during hemodialysis sessions. The primary objective of this intervention is to offer a simple, non-pharmacological method to potentially alleviate the pain associated with the cannulation process. Participants are instructed to use the stress ball for a period of three minutes before the start of cannulation. This activity is hypothesized to focus the participant's attention and possibly reduce the perception of pain, contributing to a more comfortable and less distressing cannulation experience.
Study NCT06235021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saffron
Description: Saffron powder (purchased from Moayeri Copmany2 in Oman, prepared from the stigma of Crocus sativus L.).~Total of 10 mg of saffron powder will be added to 100 ml of distilled water. Then, it will be incubated on a shaker for 24 h. The material will be passed through several layers of muslin cloth. The extracts will then be poured into a round bottom balloon and placed in the freezer at a temperature of -80°C. After freezing, the extracts were placed in a freeze-dryer.~In vacuum, the solvent will be removed and saffron powder will be obtained. After preparing the initial concentration, serial dilution with ratios of one-half and one-third will be performed in sterile vials and one-half of the final concentration will be discarded.~After the preparation of extract, the 0.2% saffron mouthwash will be prepared by mixing the following ingredients: 1. propylene glycol (5 g) 2. saffron extract (0.2 g) 3. polysorbate 80 (1.8 g) 4. sodium benzoate (0.2 g) 5. water (91 g).
Study NCT06235021 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chlorhexidine mouthwash
Description: commercial product of 0.2% chlorhexidine mouthwash.
Study NCT06181084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.
Study NCT06175793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASPIRE Intervention
Description: In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
Study NCT05589051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink
Description: Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
Study NCT05589051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Drink
Description: Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
Study NCT04690855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib 1 mg Orally Day 1 to Day 28
Study NCT04690855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
Study NCT04690855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
Study NCT04774718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
Study NCT06181084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Administered orally.
Study NCT05500469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paul glaucoma drainage device (GDD)
Description: Implantation of the GDD
Study NCT05500469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paul glaucoma drainage device (GDD)
Description: Implantation of the GDD
Study NCT06265597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Nutrition and Yoga Program
Description: * Healthy Nutrition Program~  * At the beginning of the Healthy Nutrition and Yoga Program by the researcher give education to families and children in 3 sessions (Importance of Nutrition in School Age, Obesity in School Age, Nutrition Recommendations for Obese Children).~ * Providing individual counseling to children every 2 weeks from the start of the Healthy Nutrition Program, in cooperation with a nutritionist, in line with the basic healthy eating behavior goals.~ * After the 2nd session of the healthy nutrition education and from the beginning of the Yoga Program, in the 2nd, 4th, 6th, 8th and 10th weeks, children are asked to keep a food diary for 2 weekdays and 1 weekend (Thursday-Friday-Saturday) and planning is made according to reaching basic healthy nutrition behavior goals.~* Yoga Program \*Children's yoga is applied to each group twice a week for 12 weeks.
Study NCT04757623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Purse string closure of Ileostomy
Description: conventional proceedure
Study NCT06534632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's colostrum
Description: Oropharyngeal administration of mother's colostrum
Study NCT06534632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oropharyngeal administration of sterile water
Study NCT05563636 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: standard pulsed radio frequency (PRF)
Description: patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
Study NCT05563636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-voltage long-term pulsed radio frequency (PRF)
Description: patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
Study NCT06398613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: extended pelvic lymph node dissection (ePLND)
Description: Prostate-Specific Membrane Antigen Emission Tomography/Computed Tomography (PSMA PET/CT) will done preoperatively in both arms of the study. In arm A all patients will undergo ePLND, in arm B only patients with positive PSMA PET/CT will undergo ePLND
Study NCT04969900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: The placebo group will receive placebo oil.
Study NCT04969900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender oil.
Description: Investigational Product. This group will receive Lavender oil.
Study NCT05470868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naphazoline / Hypromellose Ophthalmic
Description: Naphazoline 0.03% / Hypromellose 0.2%
Study NCT05198960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants
Description: Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
Study NCT05198960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose aspirin
Description: Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
Study NCT06041854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft combined with Enamel Matrix derivative
Description: The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex.
Study NCT05695053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low level laser therapy could provide energy to trigger cell differentiation.
Study NCT05695053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05403801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAMP+CBT application
Description: Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
Study NCT05922358 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anti-allergic treatment
Description: For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h\*1h, 45ml/h\*1h, then 225ml/h\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h\*0.5h, then 150ml/h\*3 hours.
Study NCT06247839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 (Brand name of psilocybin to be used)
Study NCT05684328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WLI Then NBI Withdrawal
Description: Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
Study NCT05684328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NBI Then WLI Withdrawal
Description: Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
Study NCT06381453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab Auto-Injector [Benlysta]
Description: Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector
Study NCT05706506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT06400485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-676
Description: Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
Study NCT04990349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
Study NCT04990349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
Study NCT06507306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198
Study NCT06507306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Oral osimertinib
Study NCT06041854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried bone allograft
Description: The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed.
Study NCT05315076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic Manipulation Posterior anterior and conventional therapy
Description: A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.